Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis

Abstract

We have analysed data on exacerbation rates, Expanded Disability Status Scale (EDSS) scores, and lesion burdens using the results of two neutralizing antibody (NA B) assays (C PE and MxA) from the pivotal relapsing-remitting multiple sclerosis (MS) trial of interferon beta-1b (IFNB) with a longitudinal appro ach, where the influence of NA Bs in individual patients is assessed by comparing responses during NAB- positive and NA B-negative periods. There are apparent influences on exacerbation rate related to dose of IFNB, titer level, and duration of positivity. With the MxA assay, exacerbation rates after switching to NA B-positive status are estimated to be 28% higher [95% confidence interval (CI): (-15%, 92%)] and -2% higher [95% CI: (-21%, 21%)] on the low- and high-dose IFNB arms, respectively. When compared with all NA B-negative periods, exacerbation rates during NA B-positive periods are estimated to be 29% higher [95% C I: (0%, 67%)] and 18% higher [95% CI: (0%, 40%)] on the low- and high-dose IFNB arms, respectively. When NA B-positive patients again become NA B-negative, no evidence of increased exacerbation rates could then be demonstrated. More detailed exploratory analyses indicate that the effects are most evident in the approximately 20% of patients developing high titers. In these patients, the influence of NABs may be self-limited, as titers often diminish or NA Bs become undetectable with time.

Keywords

EDSS scores exacerbation rates generalized estimating equations longitudinal data T2 lesion burdens

Get full access to this article

View all access options for this article.

References

IFNB Multiple Sclerosis Study Group , University of British Columbia MS/MRI Analysis Group . Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years . Neurology 1996; 47: 889-894 .

Files JG , Gray JL , Do LT , Foley WP , Gabe JD , Nestaas E et al. A novel sensitive and selective bioassay for human type I interferons . J Interferon Cytokine Res 1998; 18: 1019-1024 .

Pungor E , Files JG , Gabe JD , Do LT , Foley WP , Gray JL et al. A novel bioassay for the determination of neutralizing antibodies to interferon beta-1b . J Interferon Cytokine Res 1998; 18: 1025-1030 .

Arnason BG , Dianzani F. Correlation of the appearance of anti-interferon antibodies during treatment and diminution of efficacy: summary of an international workshop on anti-interferon antibodies . J Interferon Cytokine Res 1998; 18: 639-644 .

Liang KY , Zeger SL. Longitudinal data analysis using generalized linear models . Biometrika 1986; 73: 13-22 .

Zeger SL , Liang KY. Longitudinal data analysis for discrete and continuous outcomes . Biometrics 1986; 42: 121-130 .

Zeger SL , Liang KY. An overview of methods for the analysis of longitudinal data . Statist Med 1992; 11: 1825-1839 .

Liang KY , Zeger SL. Regression analysis for correlated data . Annu Rev Pub Health 1993; 14: 43-68 .

Rudick RA , Simonian NA , Alam JA , Campion M , Scaramucci JO , Jones W et al. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis . Neurology 1998; 50: 1266-1272 .

10.

IFNB Multiple Sclerosis Study Group . Interferon beta-1b is effective in relapsing -remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial . Neurology 1993; 43: 655-661 .

11.

Paty DW , Li DKB , UBC MS/MRI Study Group , IFNB Multiple Sclerosis Study Group . Interferon beta-1b is effective in relapsing -remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial . Neurology 1993; 43: 662-667 .

12.

IFNB Multiple Sclerosis Study Group , University of British Columbia MS/MRI Analysis Group . Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial . Neurology 1995; 45: 1277-1285 .

13.

Jacobs LD , Cookfair DL , Rudick RA , Herndon RM , Richert JR , Salazar AM et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis . Ann Neurol 1996; 39: 285-294 .

14.

PRISMS (Prevention of Relapses and Disability by Interferon b-1a Subcutaneously in Multiple Sclerosis) Study Group . Randomized double-blind placebo-controlled study of inter-feron b-1a in relapsing/remitting multiple sclerosis . Lancet 1998; 352: 1498-1504 .

15.

European Study Group on Interferon b-1b in Secondary Progressive Multiple Sclerosis . Placebo-controlled multicentre randomized trial of interferon b-1b in treatment of secondary progressive multiple sclerosis . Lancet 1998; 352: 1491-1497 .

16.

Goodkin DE , North American Study Group . Interferon b-1b in secondary progressive multiple sclerosis: clinical and MRI results of a 3-year randomized controlled trial (abstract) . Neurology 2000; 54: 2352-2352 .

17.

McFarland HF. Comparative analysis of the outcome of two phase III studies of interferon b-1b (abstract) . Neurology 2000; 54: 2352-2352 .

18.

SPECTRIMS (Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon b-1a in Multiple Sclerosis) Study Group . Randomized controlled trial of interferon b-1a in secondary progressive multiple sclerosis: clinical results . Neurology 2001; 56: 1496-1504 .

19.

Calabresi PA , Frank JA , Maloni HW , Bash CN , Stone LA , McFarland HF et al. Association between neutralizing antibodies to interferon beta and contrast enhancing lesions in multiple sclerosis (abstract) . Neurology 1997; 48: A80-A80 .

20.

Oger JJF , Vorobeychick G , Al-Fahim A , Aziz T , Edan G , Paty DW et al. Neutralizing antibodies in Betaseron-treated multiple sclerosis patients and in vitro immune function before treatment (abstract) . Neurology 1997; 48: A80-A80 .

21.

Antonelli G , Bagnato F , Pozzilli C , Simeoni E , Bastianelli S , Currenti M et al. Development of neutralizing antibodies in patients with relapsing -remitting multiple sclerosis treated with interferon beta-1a . J Interferon Cytokine Res 1998; 18: 345-350 .

22.

Zipp F , Weller M , Calabresi PA , Frank JA , Bash CN , Dichgans J et al. Increased serum levels of soluble CD95 (APO-1/Fas) in relapsing -remitting multiple sclerosis . Ann Neurol 1998; 43: 116-120 .

23.

Diggle PJ , Heagerty P , Liang KY , Zeger SL. Analysis of long-itudinal data, second edition. Oxford: Oxford University Press , 2002.

24.

Oberg K , McKenna RM. The incidence and clinical significance of antibodies to interferon-b. In Reder AT ed., Interferon therapy of multiple sclerosis. New York: Marcel Dekker , 1997: 509-521.

25.

Leroy V , Baud M , De Traversay C , Maynard-Muet M , Lebon P , Zarski JP et al. Role of interferon antibodies in breakthrough occurrence during alpha 2a and 2b therapy in patients with chronic hepatitis C . J Hepatol 1998; 28: 375-381 .

26.

Hoffmann RM , Berg T , Teuber G , Prummer O , Leifeld L , Jung MC et al. Interferon antibodies and the breakthrough phenomenon during ribavirin/interferon-alpha combination therapy and interferon-alpha monotherapy of patients with chronic hepatitis C . Z Gastroenterol 1999; 37: 715-723 .

27.

Rice GPA , Paszner B , Oger J , Lesaux J , Paty D , Ebers G et al. The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b . Neurology 1999; 52: 1277-1279 .